136 related articles for article (PubMed ID: 11847421)
1. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
Meenakshi A; Kumar RS; Kumar NS
Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185.
Meenakshi A; Kumar RS; Ganesh V; Sivakumar N
Hum Antibodies; 2003; 12(4):123-7. PubMed ID: 15156100
[TBL] [Abstract][Full Text] [Related]
3. Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study.
Meenakshi A; Kumar RS; Siva Kumar N; Ganesh V
Hum Antibodies; 2002; 11(3):73-7. PubMed ID: 12454367
[TBL] [Abstract][Full Text] [Related]
4. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
5. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
6. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
7. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K
Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Meenakshi A; Sivakumar N; Kumar RR; Shankar SG; Dean CJ; Modjtahedi H
Hum Antibodies; 1999; 9(3):149-54. PubMed ID: 10690627
[TBL] [Abstract][Full Text] [Related]
9. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP; Stern DF
Cancer Res; 1995 May; 55(9):1946-55. PubMed ID: 7728765
[TBL] [Abstract][Full Text] [Related]
10. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue.
Corbett IP; Henry JA; Angus B; Watchorn CJ; Wilkinson L; Hennessy C; Gullick WJ; Tuzi NL; May FE; Westley BR
J Pathol; 1990 May; 161(1):15-25. PubMed ID: 1973458
[TBL] [Abstract][Full Text] [Related]
11. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
[TBL] [Abstract][Full Text] [Related]
13. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Boente MP; Berchuck A; Whitaker RS; Kalén A; Xu FJ; Clarke-Pearson DL; Bell RM; Bast RC
Gynecol Oncol; 1998 Jul; 70(1):49-55. PubMed ID: 9698473
[TBL] [Abstract][Full Text] [Related]
14. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
Maier LA; Xu FJ; Hester S; Boyer CM; McKenzie S; Bruskin AM; Argon Y; Bast RC
Cancer Res; 1991 Oct; 51(19):5361-9. PubMed ID: 1680547
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
17. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
Pupa SM; Ménard S; Andreola S; Colnaghi MI
Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
[TBL] [Abstract][Full Text] [Related]
18. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
Dean CJ; Eccles SA; Valeri M; Box G; Allan S; McFarlane C; Sandle J; Styles J
Cell Biophys; 1993; 22(1-3):111-27. PubMed ID: 7534210
[TBL] [Abstract][Full Text] [Related]
19. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
